Cairo Sarah B, Arbuthnot Mary, Boomer Laura A, Dingeldein Michael W, Feliz Alexander, Gadepalli Samir, Newton Chris R, Ricca Robert, Vogel Adam M, Rothstein David H
Department of Pediatric Surgery, John R. Oishei Children's Hospital, 1001 Main Street, Buffalo, NY, 14203, USA.
Department of Pediatric and General Surgery, Naval Medical Center Portsmouth, Portsmouth, USA.
Pediatr Surg Int. 2018 Nov;34(11):1163-1169. doi: 10.1007/s00383-018-4337-y. Epub 2018 Aug 21.
Review current practices and expert opinions on contraindications to extracorporeal membrane oxygenation (ECMO) in congenital diaphragmatic hernia (CDH) and contraindications to repair of CDH following initiation of ECMO.
Modified Delphi method was employed to achieve consensus among members of the American Pediatric Surgical Association Critical Care Committee (APSA-CCC).
Overall response rate was 81% including current and former members of the APSA-CCC. An average of 5-15 CDH repairs were reported annually per institution; 26-50% of patients required ECMO. 100% of respondents would not offer ECMO to a patient with a complex or unrepairable cardiac defects or lethal chromosomal abnormality; 94.1% would not in the setting of severe intracranial hemorrhage (ICH). 76.5% and 72.2% of respondents would not offer CDH repair to patients on ECMO with grade III-IV ICH or new diagnosis of lethal genetic or metabolic abnormalities, respectively. There was significant variability in whether or not to repair CDH if unable to wean from ECMO at 4-5 weeks.
Significant variability in practice pattern and opinions exist regarding contraindications to ECMO and when to offer repair of CDH for patients on ECMO. Ongoing work to evaluate outcomes is needed to standardize management and minimize potentially futile interventions.
V (expert opinion).
回顾关于先天性膈疝(CDH)体外膜肺氧合(ECMO)的禁忌证以及ECMO启动后CDH修复的禁忌证的当前实践和专家意见。
采用改良德尔菲法在美国小儿外科协会重症监护委员会(APSA - CCC)成员之间达成共识。
总体回复率为81%,包括APSA - CCC的现任和前任成员。每个机构每年平均报告5 - 15例CDH修复手术;26 - 50%的患者需要ECMO。100%的受访者不会为患有复杂或无法修复的心脏缺陷或致命染色体异常的患者提供ECMO;94.1%的受访者在严重颅内出血(ICH)的情况下不会提供。76.5%和72.2%的受访者分别不会为患有III - IV级ICH或新诊断出致命遗传或代谢异常的ECMO患者提供CDH修复。如果在4 - 5周时无法从ECMO撤机,是否修复CDH存在显著差异。
关于ECMO的禁忌证以及何时为ECMO患者提供CDH修复,实践模式和意见存在显著差异。需要持续开展评估结果的工作,以规范管理并尽量减少潜在的无效干预。
V(专家意见)